These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25927026)

  • 21. Estradiol supplementation during the luteal phase of IVF-ICSI patients: a randomized, controlled trial.
    Serna J; Cholquevilque JL; Cela V; Martínez-Salazar J; Requena A; Garcia-Velasco JA
    Fertil Steril; 2008 Dec; 90(6):2190-5. PubMed ID: 18191847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of intracytoplasmic sperm injection in non-male factor infertility in advanced maternal age.
    Tannus S; Son WY; Gilman A; Younes G; Shavit T; Dahan MH
    Hum Reprod; 2017 Jan; 32(1):119-124. PubMed ID: 27852688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
    Yu LP; Liu N; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
    [No Abstract]   [Full Text] [Related]  

  • 27. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles.
    Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O
    Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles-A Systematic PRISMA Review and Meta-analysis.
    Haahr T; Roque M; Esteves SC; Humaidan P
    Front Endocrinol (Lausanne); 2017; 8():116. PubMed ID: 28638367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study.
    Ismail Madkour WA; Noah B; Abdel Hamid AM; Zaheer H; Al-Bahr A; Shaeer M; Moawad A
    Hum Fertil (Camb); 2016 Jun; 19(2):142-9. PubMed ID: 27434094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
    Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
    Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis.
    Gelbaya TA; Kyrgiou M; Tsoumpou I; Nardo LG
    Fertil Steril; 2008 Dec; 90(6):2116-25. PubMed ID: 18178194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
    Razieh DF; Maryam AR; Nasim T
    Taiwan J Obstet Gynecol; 2009 Sep; 48(3):245-8. PubMed ID: 19797013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.